"Overall, this study demonstrates the feasibility of applying QPOP as a functional combinatorial precision medicine platform to predict therapeutic sensitivities in AML and provides the basis for ...

The 2024 ELN risk stratification was developed with evidence from an exploratory analysis of pooled data from the phase 3 VIALE-A trial and a phase 1 b study of azacitidine plus venetoclax.

Data elements obtained from the clinical databases for the three recent multinational openlabel clinical trials included patient age, sex, race, AML classification, the duration of first remission ...

Petersburg, Florida. Children with Down syndrome have a higher risk of developing AML before age 5. Callie undergoes chemotherapy cycles with long hospital stays, and her parents find support in the ...